Clinical Trial Update: A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II study of single-agent lenalidomide in relapsed or refractory T-cell non-Hodgkin's lymphoma has been terminated; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: T-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2012-01-05